DelveInsight’s, “Dry Eye Disease Pipeline Insight, 2022,” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in the Dry Eye Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key takeaways from the Dry Eye Disease Pipeline Insight Report
Recent Breakthroughs of Dry Eye Disease Treatment Landscape
Request a sample and discover the recent advances in Dry Eye Disease Medication @ Dry Eye Disease Treatment Landscape
Dry Eye Disease Overview
Dry eye disease is defined as a multifactorial disease of the tears and ocular surface that results in symptoms of discomfort, visual disturbance, and tear film instability with potential damage to the ocular surface. It is accompanied by increased osmolarity of the tear film and subacute inflammation of the ocular surface. Dry eyes can occur when tear production and drainage are not in balance. People with dry eyes either do not produce enough tears or their tears are of a poor quality. Dry eyes can develop for many reasons, including: Age, gender, medications, medical conditions (people with rheumatoid arthritis, diabetes, and thyroid problems are more likely to have symptoms of dry eyes. Also, problems with inflammation of the eyelids (blepharitis), inflammation of the surfaces of the eye, or the inward or outward turning of eyelids can cause dry eyes to develop) and other factors such as long-term use of contact lenses can be a factor in the development of dry eyes. Refractive eye surgeries, such as LASIK, can decrease tear production and contribute to dry eyes. People with dry eyes may experience irritated, gritty, scratchy or burning eyes; a feeling of something in their eyes; excess watering; and blurred vision. Symptoms include: Redness, stinging, scratching, or burning sensations, light sensitivity, watery eyes, stringy mucus near the eye and a blurry Vision. Dry eyes can be diagnosed through a comprehensive eye examination. Treatments for dry eyes aim to restore or maintain the normal amount of tears in the eye to minimize dryness and related discomfort and to maintain eye health. The primary approaches used to manage and treat dry eyes include adding tears using over-the-counter artificial tear solutions, conserving tears, increasing tear production, and treating the inflammation of the eyelids or eye surface that contributes to the dry eyes.
Dry Eye Disease Emerging Drugs
Dry Eye Disease Pipeline Therapeutic Assessment
There are approx. 50+ key companies which are developing the therapies for Dry Eye Disease. The companies which have their Dry Eye Disease drug candidates in the most advanced stage, i.e. phase III include, RegeneRx Biopharmaceuticals.
DelveInsight’s Dry Eye Disease Pipeline report covers around 50+ products under different phases of clinical development like
Learn more about the emerging Dry Eye Disease pipeline therapies @ Dry Eye Disease Clinical Trials
Scope of the Dry Eye Disease Pipeline Report
Table of Content
Key Questions
Current Treatment Scenario and Emerging Therapies:
Got Queries? Get in touch with our Business Development Executive @ Dry Eye Disease Market Drivers and Barriers
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/